• PDF: Delivered by email usually within 48 UK business hours.

Progenics Pharmaceuticals, Inc. (PGNX) - Pharmaceuticals & Healthcare
Deals and Alliances Profile

  • Publication Date:March 2011
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:135

Progenics Pharmaceuticals, Inc. (PGNX) - Pharmaceuticals & Healthcare Deals and Alliances Profile

Progenics Pharmaceuticals, Inc. (PGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products. The company's is principally operating in the developing the drugs in the gastroenterology, virology and oncology segments. Progenics' principal programs are focused on symptom management and supportive care and the treatment of Human Immunodeficiency Virus (HIV) infection, cancer gastroenterology and virology.

In gastroenterology segment, the company is developing methylnaltrexone, a selective, peripheral, opioid-receptor antagonist for certain side effects. The company has license and co-development agreement with Wyeth Pharmaceuticals for development and commercialization of methylnaltrexone.

The company is having Relistor as its commercialized product. Relistor (methylnaltrexone bromide) subcutaneous injection received approval in Canada for opioid-induced constipation. Progenics is having further development regarding Relistor with Wyeth.

Progenics is developing viral-entry inhibitors in Virology segment. PRO 140, ProVax, and Hepatitis C Viral Entry Inhibitor are in the clinical trials. In the oncology segment, Progenics is focused on immunotherapies for prostate cancer consists of monoclonal antibodies for Prostate Specific Membrane Antigen (PSMA). In addition, the company is developing vaccines for stimulating an immune response to PSMA.

Progenics Pharmaceuticals, Inc. (PGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you an in-depth data and trend analysis of the company's mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.

Data presented in this report was derived from GlobalData's proprietary in-house Pharmaceuticals and Healthcare eTrack deals database and primary and secondary research.

Scope

  • Financial Deals - Analysis of the company's financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information on the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information on the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region for North America, Europe, the Middle East and Africa and South and Central America.
  • Deals by Market - Chart and table showing information on the number of deals and value reported by the company, by market.
  • Major Recent Deals - Information on the company's major recent financial deals. Each such deal has a brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key Competitors - A list of key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements.

  • The profile analyzes the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divesture strategy

  • Deals are presented from the company's core business segments' perspective to help you understand its corporate strategy

Access detailed information about the company's recent financial deals that enables you to understand the key deals which have shaped the company

  • Major recent deals are presented in detail, which provides information on each deal's brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company to identify potential customers and suppliers.

  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and their biographies and key competitors.

Stay up to date on the major developments affecting the company

  • Recent developments in the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research.

  • Key elements such as break up of deals by categories and information on detailed major deals are incorporated in the profile to assist your academic or business research needs.

This report covers the following industry codes:
SIC Code: 2834
NAICS Code: 325412

  • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
    • Asset Purchase
    • Progenics Pharmaceuticals Acquires Portion Of Royalty For methylnaltrexone
    • Partnerships
    • Progenics Pharmaceuticals Extends Its Commercialization Agreement With Wyeth Pharmaceuticals
    • Progenics Pharmaceuticals Enters Into Agreement With Seattle Genetics
    • Wyeth Enters Into Co-Development Agreement With Progenics Pharmaceuticals
    • Licensing Agreements
    • Salix Pharmaceuticals Enters Into Licensing Agreement With Progenics Pharmaceuticals For Relistor
    • Ono Pharmaceutical Enters Into Licensing Agreement With Progenics Pharmaceuticals
    • Equity Offering
    • Progenics Pharmaceuticals Completes Public Offering Of $60 Million
    • Progenics Pharmaceuticals Completes Public Offering Of $60 Million
    • Progenics Pharmaceuticals Completes Public Offering Of $29 Million
    • Progenics Pharmaceuticals Completes Public Offering Of $31 Million
    • Acquisition
    • Progenics Pharmaceuticals Acquires PSMA Development Company From Cytogen
    • Key Competitors
    • Key Employees
    • Locations And Subsidiaries
    • Head Office
    • Recent Developments
    • Financial Announcements
    • Mar 15, 2011: Progenics Reports Net Loss Of $18.8m For Q4 2010
    • Nov 08, 2010: Progenics Reports Net Loss Of $17.1 Million For Q3 2010
    • Aug 09, 2010: Progenics Reports Net Loss Of $15.2 Million For Q2 2010
    • May 10, 2010: Progenics Reports Net Loss Of $18.6 Million For Q1 2010
    • Mar 15, 2010: Progenics Posts Net Loss Of $0.6 Million In Q4 2009
    • Nov 09, 2009: Progenics Q3 2009 Net Loss Increases
    • Aug 06, 2009: Progenics Reports Net Loss Of $15.2 Million For Q2 2009
    • May 11, 2009: Progenics Q1 2009 Net Loss Narrows
    • Mar 13, 2009: Progenics Reports Net Loss Of $14.6 Million For Q4 2008
    • Nov 10, 2008: Progenics Reports Third Quarter 2008 Financial Results And Corporate Updates
    • Aug 08, 2008: Progenics Pharmaceuticals Reports Second Quarter 2008 Results
    • May 09, 2008: Progenics Pharmaceuticals Reports First Quarter 2008 Results
    • Mar 17, 2008: Progenics Pharmaceuticals Reports Fourth Quarter And Year End Results
    • Nov 08, 2007: Progenics Pharmaceuticals Reports Third Quarter 2007 Results
    • Aug 08, 2007: Progenics Pharmaceuticals Reports Second Quarter 2007 Results
    • May 09, 2007: Progenics Pharmaceuticals Reports First Quarter 2007 Results
    • Mar 15, 2007: Progenics Pharmaceuticals Reports Fourth Quarter And Year End Results
    • Nov 09, 2006: Progenics Pharmaceuticals Reports Third Quarter 2006 Results
    • Aug 08, 2006: Progenics Pharmaceuticals Reports Second Quarter 2006 Results
    • May 09, 2006: Progenics Pharmaceuticals Reports First Quarter 2006 Results; Loss Narrows As Mntx Development Costs Are Reimbursed And A Portion Of The Upfront Payment From Wyeth Is Recognized As Revenue
    • Mar 15, 2006: Progenics Pharmaceuticals Reports Fourth Quarter And Year End Results
    • Nov 07, 2005: Progenics Pharmaceuticals Reports Third Quarter 2005 Results
    • May 10, 2005: Progenics Pharmaceuticals Reports First Quarter 2005 Results
    • Mar 16, 2005: Progenics Pharmaceuticals Reports Fourth Quarter And Year End Results
    • Nov 09, 2004: Progenics Pharmaceuticals Reports Third Quarter 2004 Results
    • Aug 09, 2004: Progenics Pharmaceuticals Reports Second Quarter 2004 Results
    • May 07, 2004: Progenics Pharmaceuticals Reports First Quarter 2004 Results
    • Mar 15, 2004: Progenics Pharmaceuticals Reports Fourth Quarter And Year End Results
    • Oct 31, 2003: Progenics Pharmaceuticals Reports Third Quarter 2003 Results
    • Jul 30, 2003: Progenics Pharmaceuticals Reports Second Quarter 2003 Results; Company Awarded $7.7 Million In Grants From National Institutes Of Health
    • May 15, 2003: Progenics Pharmaceuticals Reports First Quarter 2003 Results
    • Mar 31, 2003: Progenics Pharmaceuticals Reports Fourth Quarter And Year End Results
    • Nov 04, 2002: Progenics Pharmaceuticals Reports Third Quarter 2002 Results
    • Aug 07, 2002: Progenics Pharmaceuticals Reports Second Quarter 2002 Results
    • May 10, 2002: Progenics Pharmaceuticals Reports First Quarter 2002 Results
    • Mar 13, 2002: Progenics Pharmaceuticals Reports Fourth Quarter And Year End Results
    • Oct 31, 2001: Progenics Pharmaceuticals Reports Third Quarter 2001 Results
    • Aug 06, 2001: Progenics Pharmaceuticals Reports Second Quarter 2001 Results
    • May 15, 2001: Progenics Pharmaceuticals Reports First Quarter 2001 Results
    • Mar 21, 2001: Progenics Pharmaceuticals Reports Fourth Quarter And Year End Results
    • Oct 26, 2000: Progenics Pharmaceuticals, Inc. Reports Third Quarter 2000 Results
    • Aug 01, 2000: Progenics Pharmaceuticals, Inc. Reports Second Quarter 2000 Results
    • May 04, 2000: Progenics Pharmaceuticals, Inc. Reports First Quarter 2000 Results
    • Corporate Communications
    • Mar 09, 2011: Progenics Pharmaceuticals Names Mark Baker As CEO
    • Jun 10, 2010: Progenics Elects Peter Crowley As Chairman
    • Sep 16, 2009: Progenics Makes Management Changes
    • Sep 16, 2009: Progenics Appoints Mark Baker As President And Director
    • Feb 04, 2009: Progenics Appoints Peter Crowley As Independent Board Member
    • Jan 27, 2000: Progenics Announces Promotion And New Appointment
    • Product News
    • Dec 20, 2006: Wyeth And Progenics Initiate Second Global Phase 3 Trial Of Intravenous Methylnaltrexone To Treat Post-Operative Ileus
    • Dec 20, 2002: Progenics Initiates Methylnaltrexone Phase-3 Clinical Program For Opioid-Induced Constipation
    • Dec 19, 2002: Cytogen And Progenics Initiate Phase I Clinical Testing Of New Therapeutic Prostate Cancer Vaccine
    • Dec 14, 2006: Progenics Achieves Enrollment Target In Clinical Trial Of Hiv Entry Inhibitor Pro 140
    • Dec 03, 2004: Progenics Achieves Enrollment Target In Pivotal Phase 3 Clinical Trial Of Methylnaltrexone For Opioid-Induced Constipation
    • Dec 01, 2005: Progenics Pharmaceuticals Initiates Clinical Trial Of Viral-Entry Inhibitor Pro 140 In Hiv-Infected Patients; Monoclonal Antibody Designed To Block Hiv Infection Of Immune System Cells
    • Nov 28, 2000: Progenics Starts Phase Ii Trial Of Pro 542 In Hiv Infected Children
    • Nov 21, 2003: Progenics Initiates Clinical Study Of New Oral Form Of Methylnaltrexone
    • Nov 21, 2002: Progenics And Cytogen Report Psma Antibody Arrested Prostate Cancer Growth In Vivo
    • Nov 17, 2008: Progenics Announces Wyeth Has Received Relistor Approval In Australia
    • Nov 10, 2000: Progenics And Cytogen Develop Antibodies To Treat Prostate Cancer
    • Oct 26, 2008: Progenics Reports Positive Interim Phase 2 Results For Two Dosage Forms 0f Novel Hiv Therapy Pro 140
    • Oct 26, 2001: Progenics Enters Collaboration With Formatech To Develop Improved Dosing Formulations For Investigational Hiv Drug Pro 542
    • Oct 16, 2001: Progenics Reports Positive Phase Ii Clinical Results For Methylnaltrexone
    • Oct 15, 2007: Wyeth And Progenics To Initiate Phase 2 Trials Of Oral Methylnaltrexone In Chronic-Pain Setting
    • Oct 10, 2003: Progenics Reports Methylnaltrexone Activity In Reversing Opioid-Induced Urinary Retention; Mntx May Also Reduce Hivs Ability To Infect Cells In Opioid-Treated Patients
    • Oct 07, 2004: Progenics Announces Achievement Of Enrollment Target In Phase 2 Clinical Trial Of Methylnaltrexone For Post-Operative Ileus
    • Oct 05, 1999: New Studies Show Progenics Drug To Be Potent Hiv Inhibitor
    • Oct 02, 2008: Progenics Announces Progress And Presentations In Hiv Therapy Program
    • Oct 01, 2001: Progenics Acquires Drug In Late-Stage Clinical Development That Blocks Debilitating Side Effects Of Opioid Pain Therapy
    • Sep 30, 2005: Progenics Achieves Enrollment Target In Second Pivotal Phase 3 Clinical Trial Of Methylnaltrexone For Opioid-Induced Constipation
    • Sep 27, 2002: Progenics Reports Positive Results Of Completed Phase Ii Clinical Study Of Hiv Entry Inhibitor Pro 542
    • Sep 27, 1999: Progenics Reports Positive Clinical Results For Hiv Therapy
    • Sep 25, 2000: Progenics And Cytogen Select Therapeutic Prostate Cancer Vaccine For Human Testing
    • Sep 23, 2002: Progenics And Cytogen Report Positive Preclinical Results For Experimental Prostate Cancer Drug
    • Sep 20, 2006: Progenics And Wyeth Initiate Global Phase 3 Clinical Program Of Intravenous Methylnaltrexone To Treat Post-Operative Ileus
    • Sep 13, 2010: Progenics' Humanized Monoclonal Antibodies Significantly Improve Survival In Animal Model Of C. difficile-Associated Disease
    • Sep 11, 2007: Wyeth And Progenics Initiate New Clinical Studies To Investigate Additional Patient Populations For Methylnaltrexone
    • Sep 09, 2005: Progenics Reports Positive Results From Phase 1 Clinical Trial Of Pro 140, A Novel Monoclonal Antibody That Blocks Hiv Entry; Single Dose Coats Immune Cells For Two Months, Potential Long-Acting Hiv Therapy
    • Sep 06, 2001: Progenics And Cytogen Develop Novel Prostate Cancer Vaccine In Collaboration With Alphavax
    • Aug 31, 2010: Progenics To Present Preclinical Study Of Monoclonal Antibodies Against C. difficile At ICAAC 2010
    • Aug 29, 2007: Wyeth And Progenics Submit Marketing Application In Australia For Subcutaneous Methylnaltrexone
    • Aug 22, 2006: Wyeth And Progenics Pharmaceuticals Announce Initiation Of Phase 2 Clinical Trial Of Oral Methylnaltrexone
    • Aug 22, 2005: Progenics Reports Additional Positive Results From Methylnaltrexone Phase 3 Clinical Trial
    • Aug 04, 2009: Progenics Pharmaceuticals Submits sNDA For New Delivery System
    • Aug 04, 2009: New Delivery System For Relistor In Pre-Filled Syringes Submitted For U.S. And European Marketing Approval
    • Jul 26, 2005: Progenics Completes Enrollment In Phase 1 Clinical Trial Of Pro 140, A Novel Hiv Entry Inhibitor Targeting Ccr5 - Potent Synergy Reported Between Pro 140 And Small-Molecule Ccr5 Antagonists -
    • Jul 20, 2007: Wyeth And Progenics Announce Positive Preliminary Results Of Phase 1 Study Of New Oral Formulation Of Methylnaltrexone
    • Jul 20, 2000: Progenics Announces Publication Of Encouraging Clinical Results With Hiv Drug
    • Jul 17, 2006: Wyeth And Progenics Announce Methylnaltrexone Receives Fda Fast Track Designation For Treatment Of Postoperative Ileus
    • Jul 12, 2000: Progenics Reports Pro 542 And T-20 Combination Synergistic Against Hiv
    • Jul 08, 2002: Progenics' Hiv Entry Inhibitor, Pro 542, Continues To Provide Encouraging Phase Ii Results
    • Jun 08, 2009: Progenics, Ono Pharmaceutical To Initiate RELISTOR Clinical Trials
    • Jun 08, 2009: Progenics To Discontinue Hepatitis-C Program
    • Jun 07, 2004: Progenics And Cytogen Provide Schedule For Psma-Related Presentations A The American Society Of Clinical Oncology Annual Meeting
    • Jun 02, 2003: Progenics Presents Results From Methylnaltrexone Clinical Trial At Cancer Conference
    • May 31, 2007: Progenics And Wyeth Announce Fda Has Accepted For Filing The New Drug Application For Subcutaneous Methylnaltrexone
    • May 28, 2008: New England Journal Of Medicine Publishes Results From A Relistor Phase 3 Clinical Study
    • May 27, 2010: Progenics Presents Preclinical Data On Monoclonal Antibodies Against Clostridium difficile
    • May 26, 2000: Progenics Announces News On Cancer Vaccine Trial
    • May 25, 2004: Progenics Pharmaceuticals Successfully Completes Two, Phase 1 Clinical Studies Of Oral Methylnaltrexone
    • May 23, 2006: Positive Results From Phase 3 Clinical Study Of Methylnaltrexone Treatment For Opioid-Induced Constipation Presented At Digestive Disease Week Conference
    • May 22, 2000: Progenics Announces Promising Results With Novel Treatment For Debilitating Cancer Therapy Side Effect
    • May 20, 2002: Progenics And Cytogen Identify New Therapeutic Agent For Prostate Cancer
    • May 18, 1999: Progenics Vaccines Tested In Melanoma, Prostate, Breast Cancer And In Combination Therapy
    • May 16, 2001: Progenics Pharmaceuticals And Cytogen Report Positive Immune System Responses From Prostate Cancer Vaccine
    • May 15, 2001: Progenics Regains Rights To Cancer Vaccine Program; Initiates New International Phase Iii Clinical Trial In Melanoma
    • May 13, 2003: Progenics Initiates Phase 2 Clinical Trial Of Methylnaltrexone To Treat Post-Operative Ileus
    • May 07, 2009: Phase 3 Clinical Study Of Relistor Presented At American Pain Society Meeting Showed Positive Activity For The Treatment Of Opioid-Induced Constipation In Chronic,Non-Cancer Pain Patients
    • May 04, 2004: Progenics Initiates Human Testing Of Novel Hiv Entry Inhibitor, Pro 140; Phase 1 Trials Begin On First Monoclonal Antibody To Block Hiv Infection Of Cells Via Ccr5
    • May 01, 2007: Progenics Announces Positive Results In Clinical Trial Of Novel Hiv Therapy
    • Apr 30, 2003: Progenics Announces Results From Methylnaltrexone Phase 2 Clinical Trial In Opioid-Induced Constipation
    • Apr 24, 2008: Wyeth And Progenics Receive Positive Opinion From European Committee For Relistor For The Treatment Of Opioid-Induced Constipation In Advanced-Illness Patients
    • Apr 24, 2006: Progenics Pharmaceuticals Acquires Full Ownership Of Prostate Cancer Joint Venture
    • Apr 21, 2006: Progenics Pharmaceuticals And Wyeth Announce Plan To File Nda For Subcutaneous Methylnaltrexone In An Improved Formulation
    • Apr 12, 1999: Progenics Pharmaceuticals Provides Additional Characterization Of Gmk Cancer Vaccine
    • Apr 05, 2001: Progenics Pharmaceuticals' Published Study Describes Benefits Of Combining Two Investigational Drugs To Block Hiv Infection
    • Mar 30, 2007: Progenics And Wyeth Announce Submission Of New Drug Application For The Subcutaneous Formulation Of Methylnaltrexone For The Treatment Of Opioid-Induced Constipation In Patients Receiving Palliative Care
    • Mar 18, 2002: Progenics' Investigational Hiv Entry Inhibitor, Pro 542, Reduced Viral Loads In Patients Failing Conventional Therapy
    • Mar 12, 2008: Wyeth And Progenics Provide Update On Phase 3 Clinical Trial Of Intravenous Methylnaltrexone For Postoperative Ileus
    • Mar 10, 2005: Progenics Announces Positive Top-Line Results From Pivotal Phase 3 Clinical Trial Of Mntx In Opioid-Induced Constipation
    • Mar 06, 2007: Wyeth And Progenics To Begin Clinical Testing Of A New Formulation Of Oral Methylnaltrexone Based On Phase 2 Findings
    • Feb 25, 2000: Progenics And Genzyme Transgenics Enter Into Development And Supply Agreement For Hiv Drug
    • Feb 22, 2006: Progenics Pharmaceuticals Hiv Drug, Pro 140, Receives Fda Fast-Track Designation
    • Feb 22, 2002: Progenics Initiates Phase Iib Clinical Study Of Investigational Drug To Reverse Side Effects Of Opioid Pain Therapy
    • Feb 15, 2006: Progenics Announces Positive Top-Line Results From Second Pivotal Phase 3 Clinical Trial Of Methylnaltrexone In Opioid-Induced Constipation; All Primary And Secondary Efficacy Endpoints Were Highly Statistically Significant
    • Feb 11, 2003: Progenics Presents New Findings From A Phase-2 Clinical Trial Of Pro 542 Hiv Entry Inhibitor
    • Feb 07, 2001: Progenics To Develop New Aids Drug To Inhibit Viral Entry And Infection; Lead Candidate Selected
    • Feb 03, 1999: Progenics Identifies Novel Antibody For Inhibiting Hiv And Presents Pro 542 Clinical Data
    • Jan 31, 2002: Progenics Pharmaceuticals Announces Promotions To Vice President
    • Jan 30, 2002: Journal Articles Highlight Clinical Use Of Progenics' Investigational Drug In Reversing Opioid Side Effects
    • Jan 24, 2001: Progenics Announces Executive Promotion
    • Jan 24, 2001: Progenics' 2 Nd Cancer Vaccine, Mgv, Induces A Two-Pronged Antitumor Immune Response In Man
    • Jan 20, 2005: Progenics Announces Positive Top-Line Results From Phase 2 Clinical Trial Of Mntx In Post-Operative Bowel Dysfunction
    • Jan 13, 2004: Progenics Initiates Second Phase 3 Clinical Trial Of Methylnaltrexone In Opioid-Induced Constipation
    • Jan 10, 2008: Progenics And Wyeth Announce Nda Review Period For Subcutaneous Methylnaltrexone Extended By Three Months
    • Jan 10, 2007: Progenics And Wyeth Announce Nda Review Period For Subcutaneous Methylnaltrexone Extended By Three Months
    • Jan 09, 2001: Progenics Reports Publication Of Encouraging Antiviral Studies Of Novel Hiv Therapy Pro 140
  • Appendix
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer 135
  • List of Tables
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts, 2009
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Deals By Therapy Area, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Progenics Pharmaceuticals Acquires Portion Of Royalty For methylnaltrexone
    • Progenics Pharmaceuticals Extends Its Commercialization Agreement With Wyeth Pharmaceuticals
    • Progenics Pharmaceuticals Enters Into Agreement With Seattle Genetics
    • Wyeth Enters Into Co-Development Agreement With Progenics Pharmaceuticals
    • Salix Pharmaceuticals Enters Into Licensing Agreement With Progenics Pharmaceuticals For Relistor
    • Ono Pharmaceutical Enters Into Licensing Agreement With Progenics Pharmaceuticals
    • Progenics Pharmaceuticals Completes Public Offering Of $60 Million
    • Progenics Pharmaceuticals Completes Public Offering Of $60 Million
    • Progenics Pharmaceuticals Completes Public Offering Of $29 Million
    • Progenics Pharmaceuticals Completes Public Offering Of $31 Million
    • Progenics Pharmaceuticals Acquires PSMA Development Company From Cytogen
    • Progenics Pharmaceuticals, Inc., Key Employees 35
  • List of Figures
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals by Year, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Licensing Deals by Phase, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
+44 20 8816 8548

Ask a question about Progenics Pharmaceuticals, Inc. (PGNX) - Pharmaceuticals & Healthcare

Enter the characters you see in the picture below
Captcha